Zymeworks Stock Price, News & Analysis (NYSE:ZYME) $9.10 +0.09 (+1.00%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$8.89▼$9.3050-Day Range$6.18▼$9.2352-Week Range$5.76▼$10.80Volume321,637 shsAverage Volume562,866 shsMarket Capitalization$637 millionP/E Ratio2.93Dividend YieldN/APrice Target$12.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Zymeworks MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside36.8% Upside$12.44 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.97) to ($1.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector630th out of 957 stocksPharmaceutical Preparations Industry265th out of 399 stocks 3.2 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.44, Zymeworks has a forecasted upside of 36.8% from its current price of $9.10.Amount of Analyst CoverageZymeworks has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Zymeworks this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.22% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions93.63% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($1.97) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is 2.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.14.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is 2.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.82.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zymeworks Stock (NYSE:ZYME)Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.Read More ZYME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesDecember 1, 2023 | seekingalpha.comZymeworks: Late-Stage Study Data In 2024 Makes This A Must-WatchDecember 1, 2023 | finance.yahoo.comDoes Zymeworks Inc. (ZYME) Have the Potential to Rally 42.84% as Wall Street Analysts Expect?December 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | finance.yahoo.comWall Street Analysts Predict a 64.61% Upside in Zymeworks Inc. (ZYME): Here's What You Should KnowNovember 9, 2023 | benzinga.comZymeworks Stock (NASDAQ:ZYME) Earnings Dates and Earning CallsNovember 8, 2023 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | seekingalpha.comZymeworks Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 7, 2023 | benzinga.comRecap: Zymeworks Q3 EarningsDecember 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 7, 2023 | msn.comZymeworks Non-GAAP EPS of -$0.38 beats by $0.09, revenue of $16.51M beats by $2.08MNovember 4, 2023 | morningstar.comZymeworks Inc Registered ShsOctober 23, 2023 | businesswire.comGlobal ADC (Antibody Drug Conjugates) Market Research Report 2023-2035: Focus on ADC Linker and ADC Conjugation Technologies - Over 420 ADCs are Currently Being Evaluated ...October 16, 2023 | finance.yahoo.comZymeworks Announces New Director NomineeSeptember 22, 2023 | benzinga.comRevolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding UncertaintySeptember 11, 2023 | msn.comAdding Zymeworks To My Value Watchlist (Initial Buy Rating)August 15, 2023 | msn.comHC Wainwright & Co. Reiterates Zymeworks BC (ZYME) Neutral RecommendationAugust 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Zymeworks (ZYME)August 11, 2023 | msn.comZymeworks GAAP EPS of -$0.76 misses by $0.27, revenue of $7M misses by $9.97MAugust 10, 2023 | seekingalpha.comZymeworks Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 10, 2023 | markets.businessinsider.comZymeworks earnings: here's what Wall Street expectsJuly 22, 2023 | fool.comZymeworks (NYSE: ZYME)July 19, 2023 | finance.yahoo.comZymeworks To Host Second Quarter 2023 Results Conference CallJune 30, 2023 | finanznachrichten.deZymeworks Inc.: Zymeworks Appoints New DirectorJune 29, 2023 | finance.yahoo.comZymeworks Appoints New DirectorJune 28, 2023 | seekingalpha.comZymeworks joins Russell 3000, Russell 2000, and Russell microcap indexesJune 26, 2023 | finanznachrichten.deZymeworks Inc.: Zymeworks Set to Join Russell 3000, Russell 2000, and Russell Microcap IndexesJune 26, 2023 | finance.yahoo.comZymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® IndexesSee More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees252Year FoundedN/APrice Target and Rating Average Stock Price Target$12.44 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+36.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$3.11 Trailing P/E Ratio2.93 Forward P/E RatioN/A P/E GrowthN/ANet Income$124.34 million Net Margins44.47% Pretax Margin47.75% Return on Equity44.62% Return on Assets34.09% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio5.14 Sales & Book Value Annual Sales$412.48 million Price / Sales1.54 Cash Flow$2.15 per share Price / Cash Flow4.23 Book Value$7.82 per share Price / Book1.16Miscellaneous Outstanding Shares70,000,000Free Float69,148,000Market Cap$637 million OptionableOptionable Beta0.97 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 60)CEO & Chairman of the Board Comp: $1.22MDr. Christopher Astle Ph.D. (Age 43)Senior VP & CFO Comp: $721.23kMs. Bijal Desai M.B.A.Executive Director of Corporate Finance, FP&A & ProcurementMr. Mark Hollywood (Age 53)Executive VP and Head of Technical & Manufacturing Operations Dr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Jack W. SpinksAssociate Director of Investor RelationsMr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsMs. Laura O'ConnorExecutive Director & Head of Global Human ResourcesDr. Jeffrey Smith M.D.Senior Vice President of Early-Stage DevelopmentMore ExecutivesKey CompetitorsWave Life SciencesNASDAQ:WVERevance TherapeuticsNASDAQ:RVNCArcturus TherapeuticsNASDAQ:ARCTCentessa PharmaceuticalsNASDAQ:CNTAVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 26,012 shares on 12/6/2023Ownership: 0.086%Wellington Management Group LLPBought 100,304 shares on 12/1/2023Ownership: 0.224%Deutsche Bank AGSold 490,281 shares on 11/24/2023Ownership: 0.164%Walleye Capital LLCBought 5,600 shares on 11/21/2023Ownership: 0.000%Jacobs Levy Equity Management Inc.Sold 115,895 shares on 11/17/2023Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions ZYME Stock Analysis - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price target for 2024? 7 equities research analysts have issued twelve-month price targets for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's stock price to reach $12.44 in the next year. This suggests a possible upside of 36.8% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2023? Zymeworks' stock was trading at $7.86 at the beginning of the year. Since then, ZYME shares have increased by 15.8% and is now trading at $9.10. View the best growth stocks for 2023 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.14. The business had revenue of $16.51 million for the quarter, compared to analyst estimates of $10.17 million. Zymeworks had a net margin of 44.47% and a trailing twelve-month return on equity of 44.62%. What ETF holds Zymeworks' stock ? Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (6.41%), Rubric Capital Management LP (3.79%), Rubric Capital Management LP (3.79%), Acadian Asset Management LLC (1.18%), AQR Capital Management LLC (1.14%) and Jupiter Asset Management Ltd. (0.70%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:ZYME) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.